Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 6 publications
First-in-Human Evaluation of Safety, Pharmacokinetics and Muscle Glycogen Lowering of a Novel Glycogen Synthase 1 Inhibitor for the Treatment of Pompe Disease.
Journal: Clinical pharmacology and therapeutics
Published: May 10, 2024
Small-molecule inhibition of glycogen synthase 1 for the treatment of Pompe disease and other glycogen storage disorders.
Journal: Science translational medicine
Published: January 17, 2024
Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial.
Journal: Clinical genitourinary cancer
Published: December 14, 2016
The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer.
Journal: European urology
Published: June 12, 2015
Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial.
Journal: The Lancet. Oncology
Published: April 19, 2015
Enzalutamide in metastatic prostate cancer before chemotherapy.
Journal: The New England journal of medicine
Published: June 03, 2014
Showing 1-6 of 6
Last Updated: 09/26/2026